





ثبكة المعلومات الجامعية





جامعة عين شمس

التوثيق الالكتروني والميكروفيلم



نقسم بللله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأفلام قد اعدت دون آية تغيرات



يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15-20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of 15-25c and relative humidity 20-40 %



ثبكة المعلومات الجامعية







STUDY OF SOME BIOCHEMICAL FACTORS IN PATHOGENESIS OF PARKINSONISM

Submitted to the Faculty of Medicine
University of Alexandria
in partial fulfillment of the requirement for

Master Degree
OF
Medical Biochemistry

By

HAZEM FARAG MANNAA

MBBCh, Alex.

Faculty of Medicine
Alexandria University
2001

B

SUPERVISORS

Prof. Dr. ENAYAT M. HASHEM

Professor of Medical Biochemistry
Faculty of Medicine
University of Alexandria

Prof. Dr. SABAH A. MAHMOUD

Professor of Medical Biochemistry
Faculty of Medicine
University of Alexandria

Dr. MOHAMED F. BORAEY

Assistant Professor of Neuropsychiatry,
Faculty of Medicine
University of Alexandria

CO-WORKER Dr. EMAN A. SHAAT

Lecturer of Medical Biochemistry
Faculty of Medicine
University of Alexandria

ACKNOWLEDGMENT

I would like to express my deepest thanks and gratitude to **Prof. Dr. ENAYAT M. HASHEM,** Professor of Medical Biochemistry, Faculty of Medicine, University of Alexandria, for her supervision, encouragement, valuable advice and moral support. To her I express my deepest gratitude.

I would like to express my profound gratitude to **Prof. Dr SABAH A. MAHMOUD,** Professor of Medical Biochemistry, Faculty of Medicine,
University of Alexandria, who suggested the subject and supervised the work
all through its stages, for her ultimate help, keen supervision, and
encouragement that helped me in every step during the accomplishment of
this work.

I am deeply grateful to **Dr. MOHAMED F. BORAEY**, Assistant Professor of Neuropsychiatry, Faculty of Medicine, University of Alexandria, who supervised and revised the whole work, for his continuous encouragement, guidance, cooperation and great support.

I would like to express my profound gratitude and appreciation to **Dr. EMAN A. SHAAT**, Lecturer of Medical Biochemistry, Faculty of Medicine,
University of Alexandria, for her great help by her experience in practical
part of the study. To her therefore, I express my deep sense of gratitude which
she will find everlasting.

Finally my great appreciation is given to all those who shared either practically or morally in the creation of this thesis.

ABBREVIATIONS

AD:

Alzheimer

ATP:

Adenosine triphosphate

CO:

Carbon monoxide

DA:

Dopamine

DNA:

Deoxyribonucloeic acid

FAD:

Flavine adenine dinucleotide

Fe²⁺:

Ferrous iron

Fe³¹:

Ferric iron

FMN:

Flavine mononucleotide

GSH:

Reduced Glutathione

GSSG:

Oxidized Glutathione

GSH-PX:

Glutathione peroxidase

H₂O:

Water

MAO:

Monoamine oxidase

Mn

Manganese

MPP+:

1-methyl-4-phenyl-pyridinium ion

MPTP:

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

NAD:

Nicotinamide adenine dinucleotide

 O_2 :

Molecular oxygen

PD:

Parkinson's disease

SN:

Substantia nigra

SOD

Superoxide dismutase

UQH₂:

Ubiquinol

Page	Line	Wrong word	Correct word
5	5	Norepinephrin	Norepinephrine
5	5	Epinephrin	Epinephrine
7	14	Unbiquinol	Ubiquinol
12	8,15,17	Unbiquinol	Ubiquinol
14	13	Form	From
15	3	Independance	Independant
37	18	Substatntia	Substantia
36	21	Substatntia	Substantia
38	2	Substatntia	Substantia
50	21	Duroeuinone	Duroquinone

INTRODUCTION

INTRODUCTION

In 1817, James Parkinson; a physician of Hoxton in London, gave the first description of the major clinical features of what today is recognized as a symptom complex manifested by any combination of six cardinal features: (1) tremor at rest, (2) rigidity, (3) bradykinesia-hypokinesia, (4) flexed posture, (5) loss of postural reflexes, and (6) the freezing phenomenon. At least two of these features, with at least one being either tremor at rest or bradykinesia must be present for a diagnosis of definite parkinsonism. (1-3)

Actiology

Parkinsonism is caused by lesions in the basal nuclei and is associated particularly with the interconnecting system between the substantia nigra and the corpus striatum. The nigrostriatal pathways utilize dopamine as a neurotransmitter, and parkinsonism is associated with dopamine deficiency. (1-3)

The many causes of parkinsonism are divided into four categories: idiopathic, symptomatic, parkinson-plus syndromes, and other neuro-degenerative diseases in which parkinsonism is a manifestation (table 1). (1,4,5)

Table 1. Classification of major parkinsonian syndromes

Idiopathic Parkinsonism

Parkinson disease

Symptomatic Parkinsonism

Drug-induced: dopamine antagonists and depletors

Hemiatrophy-Hemiparkinsonism

Hydrocephalus: normal pressure hydrocephalus

Hypoxia

Infectious; postencepalitic

Metabolic; parathyroid dysfunction Toxin: Mn, CO, MPTP, Cyanide

Trauma Tumor

Vascular; multi-infarct state

Parkinson-plus syndromes

Cortical-basal ganglionic degeneration

Dementia syndromes

Alzheimer disease

Diffuse Lewy body disease

Lytico-Bodig (Guamanian Parkinsonism-Dementia-ALS)

Multiple system atrophy syndromes

Striatonigral degeneration

Shy-Drager syndrome

Sporadic olivopotocerebellar degeneration (OPCA)

Motor neuron disease- parkinsonism

Progressive pallidal atrophy

Progressive supranuclear palsy

Heredodegenerative diseases

Hallervorden-Spatz disease

Huntington disease

Lubag (X-linked dystonia- parkinsonism)

Mitochondrial cytopathies with striatal necrosis

Neuroacanthocytosis

Wilson disease

Drug-induced parkinsonism

Secondary parkinsonism may be caused by variable drugs. Neuroleptics (antipsychotic drugs) are the commonest among this actiological group of secondary parkinsonism. Neuroleptics include; haloperidol (safinace), chlorpromazine (neuroazine), resperidone, clozapine (lebonex), and fluphenazine (mellaril).⁽⁵⁾

Pentoxifylline is a synthetic derivative of xanthine and it may cause imbalance between dopamine receptors producing pharmacologic parkinsonism, or rather, may unmask the subclinical Parkinson's disease. (6)

Amiodarone; an antiarrhythmic drug, was reported to produce some features of parkinsonism.⁽⁷⁾

Valproate (antiepileptic drug), some of the calcium channel blockers⁽⁸⁾ as deltiazim and amlodipine, and cinnarzine (a piperazine derivative with calcium antagonist and anticonvulsant properties)⁽⁹⁾ were reported to induce parkinsonism.

Incidence of Parkinson's disease

It is estimated that Parkinson's disease (PD) makes up approximately 80% of the cases of parkinsonism.⁽¹⁾

The age at onset assumes a bell-shaped curve with a mean age of 55 years in both sexes and a wide range from 20 to 80 years. Onset at younger than 20 years is known as juvenile Parkinsonism which is often hereditary or caused by Huntington disease or Wilson's disease. (1,10) Reports tell that 1% of people over the age of 50 years have this condition. (11)

Parkinson's disease is more common in males with a male/female ratio of 3/2. But as women live longer and the incidence increases with age, there are more affected older women.⁽⁴⁾

Monoamine oxidase and Dopamine Biochemistry

Monoamine oxidase (MAO) is an enzyme that oxidatively deaminates many amines. It is found in all human tissues except red blood cells.

In the 1960's, 2 isoenzymes of MAO were identified; MAO-type A (MAO-A) and MAO-type B (MAO-B). MAO-A prefers as substrates, the hydroxylated amines; norepinephrin, epinephrin, and serotonin, while MAO-B preferentially acts on nonhydroxylated amines such as phenylethylamine. (27)

MAO-A and MAO-B, differ in their amino acid sequences and are encoded and transcriptionally controlled at separate gene loci. (28,29) Both proteins are constituents of mitochondrial outer membranes but are also found in the cytosol. (30,31) MAO-A is resident in most neurons, while MAO-B is found in non-neuronal cells, particularly astrocytes. (31)

Figure(1) shows the main metabolic pathways of dopamine. Infusion of radiolabelled dopamine has shown that most is metabolized to homovanilic acid, and a lesser proportion through the catecholamine pathway to norepinephrin, epinephrin, and vanillyl mandilic acid. (29-32)